# Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

> **NCT04263038** · PHASE4 · RECRUITING · sponsor: **Drahomir Aujesky** · enrollment: 276 (estimated)

## Conditions studied

- Pulmonary Embolism
- Embolism
- Embolism and Thrombosis
- Lung Diseases
- Cardiovascular Diseases
- Respiratory Tract Diseases
- Venous Thromboembolism
- Anticoagulant-induced Bleeding
- Bleeding

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04263038
- **Lead sponsor:** Drahomir Aujesky
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-15
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263038, "Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT04263038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*